Cardiovascular safety of CDK4/6 inhibitors in advance breast cancer: Assessing risks of QTc prolongation and thrombosis
Journal of Oncology Pharmacy Practice
Published online on August 20, 2025
Abstract
Journal of Oncology Pharmacy Practice, Volume 32, Issue 3, Page 529-537, April 2026.
ObjectiveCyclin-dependent kinase (CDK) 4/6 inhibitors have become a cornerstone in the treatment of hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, demonstrating significant efficacy in both ...
ObjectiveCyclin-dependent kinase (CDK) 4/6 inhibitors have become a cornerstone in the treatment of hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, demonstrating significant efficacy in both ...